DEKA Research & Development has received 510(k) clearance from the US Food and Drug Administration (FDA) for the twiist automated insulin delivery (AID) system.

The device is designed to significantly improve insulin management for individuals aged six and above with type 1 diabetes.

Sequel Med Tech will be responsible for commercialising the twiist AID system, which is claimed to be the first drug delivery system to measure the insulin volume and flow with every micro-dose directly.

The device features Tidepool Loop technology, which allows for automatic adjustments in insulin delivery based on continuous glucose monitoring (CGM) readings and predicted glucose levels.

Tidepool Loop is a first fully interoperable automated insulin dosing app cleared by the FDA.

Tidepool president and CEO Howard Look said: “The twiist AID system takes advantage of the Tidepool Loop algorithm, the first and only FDA-cleared glycemic controller that originated as a patient-led initiative. We are thrilled to see twiist come to market and bring new advancements to people living with type 1 diabetes.”

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free
sample

Your download email will arrive shortly

We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData







Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device integrates data from a CGM device, a control algorithm, and an insulin pump to help patients manage their blood sugar levels more effectively.

Sequel CEO and co-founder Alan Lotvin said: “The clearance of the twiist AID system is a pivotal first step in Sequel’s quest to make day-to-day life easier for people with type 1 diabetes. The twiist system combines drug delivery technology that directly and precisely measures each dose of insulin, providing the opportunity for better control and flexibility.

“Sequel is working to simplify living with diabetes by introducing product and process innovation while expanding access for all. It’s why we expect to distribute twiist through the pharmacy channel so more people with type 1 diabetes have a convenient, affordable way to get started on an AID system.”


Source link